RT Journal Article
SR Electronic
T1 Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20155317
DO 10.1101/2020.07.16.20155317
A1 Laith J. Abu Raddad
A1 Hiam Chemaitelly
A1 Houssein H. Ayoub
A1 Zaina Al Kanaani
A1 Abdullatif Al Khal
A1 Einas Al Kuwari
A1 Adeel A. Butt
A1 Peter Coyle
A1 Ali Nizar Latif
A1 Robert C. Owen
A1 Hanan F. Abdul Rahim
A1 Samya A. Al Abdulla
A1 Mohamed G. Al Kuwari
A1 Mujeeb C. Kandy
A1 Hatoun Saeb
A1 Shazia Nadeem N. Ahmed
A1 Hamad Eid Al Romaihi
A1 Devendra Bansal
A1 Louise Dalton
A1 Sheikh Mohammad Al Thani
A1 Roberto Bertollini
YR 2020
UL http://medrxiv.org/content/early/2020/07/19/2020.07.16.20155317.abstract
AB Background Qatar has a population of 2.8 million, over half of whom are expatriate craft and manual workers (CMW). We aimed to characterize the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar.Methods A series of epidemiologic studies were conducted including analysis of the national SARS-CoV-2 PCR testing and hospitalization database, community surveys assessing current infection, ad-hoc PCR testing campaigns in workplaces and residential areas, serological testing for antibody on blood specimens collected for routine clinical screening/management, national Coronavirus Diseases 2019 (COVID-19) death registry, and a mathematical model.Results By July 10, 397,577 individuals had been PCR tested for SARS-CoV-2, of whom 110,986 were positive, a positivity cumulative rate of 27.9% (95% CI: 27.8-28.1%). PCR positivity of nasopharyngeal swabs in a national community survey (May 6-7) including 1,307 participants was 14.9% (95% CI: 11.5-19.0%); 58.5% of those testing positive were asymptomatic. Across 448 ad-hoc PCR testing campaigns in workplaces and residential areas including 26,715 individuals, pooled mean PCR positivity was 15.6% (95% CI: 13.7-17.7%). SARS-CoV-2 antibody prevalence was 24.0% (95% CI: 23.3-24.6%) in 32,970 residual clinical blood specimens. Antibody prevalence was only 47.3% (95% CI: 46.2-48.5%) in those who had at least one PCR positive result, but it was 91.3% (95% CI: 89.5-92.9%) among those who were PCR positive >3 weeks before serology testing. There were substantial differences in exposure to infection by nationality and sex, reflecting risk differentials between the CMW and urban populations. As of July 5, case severity rate, based on the WHO severity classification, was 3.4% and case fatality rate was 1.4 per 1,000 persons. Model-estimated daily number of infections and active-infection prevalence peaked at 31,040 and 8.0%, respectively, on May 20 and May 21. Attack rate (ever infection) was estimated at 61.3% on July 12. R0 ranged between 1.45-1.68 throughout the epidemic. Rt was estimated at 0.70 on June 15, which was hence set as onset date for easing of restrictions. Age was by far the strongest predictor of severe, critical, or fatal infection.Conclusions Qatar has experienced a large SARS-CoV-2 epidemic that is rapidly declining, apparently due to exhaustion of susceptibles. The epidemic demonstrated a classic susceptible-infected-recovered “SIR” dynamics with a rather stable R0 of about 1.6. The young demographic structure of the population, in addition to a resourced public health response, yielded a milder disease burden and lower mortality than elsewhere.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMinistry of Public Health, Hamad Medical Corporation, Primary Health Care Corporation, and Qatar National Research Fund (NPRP 9-040-3-008 and NPRP 12S-0216-190094).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies were approved by HMC and Weill Cornell Medicine-Qatar Institutional Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available at the discretionary of stakeholders.